Edrecolomab
From Wikipedia, the free encyclopedia
Edrecolomab (MAb17-1A) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with colorectal carcinoma. However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents [1]. It is important to mention that edrecolomab was well tolerated and as such research has now concentrated on whether it can be of any use in other forms of cancer.
[edit] References
- ^ Punt CJ et al, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. The Lancet, Volume 360, Issue 9334, Pages 671-677 [1]
Abagovomab, Afelimomab, Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Besilesomab, Biciromab brallobarbital, Capromab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab, Enlimomab pegol, Epitumomab, Epitumomab cituxetan, Fanolesomab, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Igovomab, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Nacolomab tafenatox, Nerelimomab, Nofetumomab merpentan, Odulimomab, Oregovomab, Pemtumomab, Pintumomab, Satumomab, Sulesomab, Taplitumomab paptox, Telimomab aritox, Tositumomab, Vepalimomab, Zolimomab aritox
